|
117 |
What is Clean in Place (CIP)?
|
관리자 |
2025-06-02 |
2,469 |
|
116 |
The Importance Of Primary And Secondary Drying And Their Impact On Lyophilization
|
관리자 |
2025-04-30 |
2,003 |
|
115 |
Why Pharma Risk Assessments Should Include 'Working Together Alone'
|
관리자 |
2025-04-30 |
1,123 |
|
114 |
When to Replace your HEPA Filter – According to a Cleanroom Expert
|
관리자 |
2025-04-30 |
1,543 |
|
113 |
Why You Need A Raw Material Control Strategy
|
관리자 |
2025-04-30 |
1,011 |
|
112 |
Sterilisation Processes – Requirements and Definitions
|
관리자 |
2025-04-01 |
1,655 |
|
111 |
How to Implement Quality Oversight at Shop Floor Level
|
관리자 |
2025-04-01 |
1,151 |
|
110 |
Quality Risk Management: What’s new in ICH Q9(R1)?
|
관리자 |
2025-04-01 |
1,625 |
|
109 |
FDA issues Warning Letter due to GMP Violations at Chinese Drug Manufacturer
|
관리자 |
2025-04-01 |
957 |
|
108 |
A Risk-based Approach To Filter Integrity Testing Annex 1 Requirements For Biologics DS
|
관리자 |
2025-02-28 |
1,450 |
